Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia

被引:37
作者
de Jonge, E
Dekkers, PEP
Creasey, AA
Hack, CE
Paulson, SK
Karim, A
Kesecioglu, J
Levi, M
van Deventer, SJH
van der Poll, T
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1100 DD Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Lab Expt Internal Med, NL-1100 DD Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1100 DD Amsterdam, Netherlands
[4] Red Cross Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands
[5] Chiron, Emeryville, CA USA
[6] Searle Res & Dev, Skokie, IL USA
关键词
D O I
10.1086/320723
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activation of coagulation induces a proinflammatory response in in vitro and animal experiments. Inhibition of the tissue factor-dependent pathway of coagulation inhibits cytokine release and prevents death in gram-negative sepsis models in primates. This study investigated the influence of blocking the coagulation system by tissue factor pathway inhibitor (TFPI) on endotoxin-induced inflammatory responses in healthy humans. Eight men were studied in a double-blind, randomized, placebo-controlled cross-over study. They received a bolus intravenous injection of 4 ng/kg of endotoxin, followed by a 6-h continuous infusion of either TFPI (0.2 mg/kg/h after a bolus of 0.05 mg/kg) or placebo. Endotoxin induced-activation of coagulation was prevented completely by TFPI. In contrast, TFPI did not influence leukocyte activation, chemokine release, endothelial cell activation, or the acute phase response. Thus, complete prevention of coagulation activation by TFPI does not influence activation of inflammatory pathways during human endotoxemia.
引用
收藏
页码:1815 / 1818
页数:4
相关论文
共 15 条
[1]  
CARR C, 1994, CIRC SHOCK, V44, P126
[2]  
CEJKA J, 1982, CLIN CHEM, V28, P1356
[3]   TISSUE FACTOR PATHWAY INHIBITOR REDUCES MORTALITY FROM ESCHERICHIA-COLI SEPTIC SHOCK [J].
CREASEY, AA ;
CHANG, ACK ;
FEIGEN, L ;
WUN, TC ;
TAYLOR, FB ;
HINSHAW, LB .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) :2850-2860
[4]   Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia [J].
de Jonge, E ;
Dekkers, PEP ;
Creasey, AA ;
Hack, CE ;
Paulson, SK ;
Karim, A ;
Kesecioglu, J ;
Levi, M ;
van Deventer, SJH ;
van der Poll, T .
BLOOD, 2000, 95 (04) :1124-1129
[5]  
DEJONGE E, 2000, CURR OPIN CRIT CARE, V6, P317
[6]   Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? [J].
Esmon, CT .
BLOOD, 2000, 95 (04) :1113-1116
[7]  
ESMON CT, 1999, SEPSIS, V3, P161
[8]   LIPOPOLYSACCHARIDE TOXICITY-REGULATING PROTEINS IN BACTEREMIA [J].
FROON, AHM ;
DENTENER, MA ;
GREVE, JWM ;
RAMSAY, G ;
BUURMAN, WA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1250-1257
[9]   Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock [J].
Goldfarb, RD ;
Glock, D ;
Johnson, K ;
Creasey, AA ;
Carr, C ;
McCarthy, RJ ;
Matushek, M ;
Akhter, I ;
Trenholme, G ;
Parrillo, JE .
SHOCK, 1998, 10 (04) :258-264
[10]  
Johnson K, 1998, J IMMUNOL, V160, P5130